Send to

Choose Destination
Clin Nucl Med. 2018 Oct 8. doi: 10.1097/RLU.0000000000002301. [Epub ahead of print]

18F-DCFPyL PET/CT in Oncocytoma.

Author information

Hanyang University College of Medicine, Seoul, South Korea.
University of British Columbia, Vancouver, British Columbia.
London Health Sciences Centre, Ontario, Canada.


A 76-year-old man with biochemical failure after primary radiotherapy for prostate cancer had no malignant disease detected on Tc-MDP bone scan and diagnostic CT. Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is overexpressed in prostate cancer cells. The PSMA-targeted F-DCFPyL PET/CT demonstrated lymph node disease and photopenic defects in the left kidney associated with a cyst and biopsy-proven oncocytoma. Prostate-specific membrane antigen is expressed in the neovasculature of several solid tumors. It has been reported that PSMA expression is seen in approximately 50% of oncocytoma versus 76% of clear cell renal carcinomas. Biopsy confirmation is needed regardless of F-DCFPyL avidity.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center